12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

HercepTest regulatory update

FDA approved the HercepTest and HER2 IQFISH pharmaDx test from Agilent's Dako A/S subsidiary to identify patients with HER2-positive metastatic breast cancer (mBC) who may be eligible for treatment with Kadcyla ado-trastuzumab emtansine ( T-DM1) from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland)....

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >